On June 1, Kelun-Biotech Biopharmaceutical rose 4.5% in regular trading, trading at 465.8 HKD/share, with trading volume of approximately 84.27 million HKD. The rally was driven by the company being named one of the Top 10 Golden Stocks for June in a major investment strategy report, alongside sustained catalysis from recent ASCO annual meeting clinical data.

The company's core TROP2 ADC drug sac-TMT has initiated 17 Phase III clinical studies. Nomura previously raised its target price to 544.42 HKD and maintained a Buy rating, noting the drug demonstrated a PFS hazard ratio of 0.35 in treating PD-L1-positive non-small cell lung cancer — making it the first ADC globally to show PFS improvement in a Phase III trial for this indication. Market estimates suggest peak overseas sales could reach $15 billion, with profitability expected by next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)